RecruitingNCT05399745

BILACO Trial: Biliary Atresia - a Severe Complex Congenital Liver Disease

BILACO Trial: Biliary Atresia - a Severe Complex Congenital Liver Disease With High Mortality, Compromised Neurological Development, Severe Malnutrition and Unknown Etiology


Sponsor

Rigshospitalet, Denmark

Enrollment

100 participants

Start Date

Mar 1, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

Biliary atresia is the most severe form of cholestatic liver disease. The children have high morbidity and mortality and get devastating pruritus and fatigue, failure to thrive, progressive hepatic failure and impaired neurodevelopment. The etiology is mostly unknown. More than half need a new liver from a living or deceased donor during childhood. However, correct timing of the transplantation is extremely difficult because of lack of consensus based on clinical assessment tools. All though the incidence is low, the cost of this disease is tremendous from both a clinical and human perspective. So far, protocolized neurodevelopment tests, genetic profiling, precise malnutrition evaluation based on clinical appearance, biochemical markers and brain MRI-scans, body composition, immunological function, level of physical activity and optimal time of transplantation in cholestatic children are unknown. The aim is to determine risk factors for neurocognitive impairment in children suffering from severe cholestasis in order to determine optimal time for liver transplantation from a brain perspective. In a prospective study, the investigators will investigate risk factors related to brain-, heart-, gut- and immunological function in the Danish cohort. This cohort consists of 75 children aged 0-18 years. In addition, 30 aged and gender matched healthy and 20 tetra fallot children will serve as control groups. The children will undergo extensive and advanced liver function evaluation, genetic profiling, nutrition and immunological status, neuro-imaging and neurocognitive evaluation at time of diagnose, 2 years of age, pre-school, pre-teenage, and teenage. In case of a liver transplantation, additional neuro-cognitive tests will be performed


Eligibility

Min Age: 0 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (the BILACO Trial) is collecting biological samples and data from children with biliary atresia (a rare liver disease where the bile ducts are blocked or absent), children with Tetralogy of Fallot (a congenital heart defect), and healthy children as controls. The goal is to better understand these congenital conditions. You may be eligible if: - You are a child (up to 18 years old) with a diagnosis of biliary atresia, Tetralogy of Fallot, or you are a healthy control You may NOT be eligible if: - You are unable to participate in the required study examinations Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNeurocognitive monitoring

Neurocognitive tests and MRI of the brain


Locations(1)

Rigshospitalet

Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05399745


Related Trials